CN112716952A - 纤维化病治疗剂 - Google Patents

纤维化病治疗剂 Download PDF

Info

Publication number
CN112716952A
CN112716952A CN202110067291.6A CN202110067291A CN112716952A CN 112716952 A CN112716952 A CN 112716952A CN 202110067291 A CN202110067291 A CN 202110067291A CN 112716952 A CN112716952 A CN 112716952A
Authority
CN
China
Prior art keywords
fibrosis
amino
present
interstitial pneumonia
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110067291.6A
Other languages
English (en)
Chinese (zh)
Inventor
藤冈秋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN112716952A publication Critical patent/CN112716952A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202110067291.6A 2015-06-25 2016-06-24 纤维化病治疗剂 Pending CN112716952A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015127788 2015-06-25
JP2015-127788 2015-06-25
CN201680037175.7A CN107708697B (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680037175.7A Division CN107708697B (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Publications (1)

Publication Number Publication Date
CN112716952A true CN112716952A (zh) 2021-04-30

Family

ID=57585165

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110067291.6A Pending CN112716952A (zh) 2015-06-25 2016-06-24 纤维化病治疗剂
CN201680037175.7A Active CN107708697B (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680037175.7A Active CN107708697B (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Country Status (20)

Country Link
US (4) US10449189B2 (https=)
EP (2) EP3973962A1 (https=)
JP (3) JP6974167B2 (https=)
KR (1) KR102647942B1 (https=)
CN (2) CN112716952A (https=)
AU (1) AU2016284531B2 (https=)
BR (1) BR112017028137B1 (https=)
CA (1) CA2990791A1 (https=)
DK (1) DK3315131T3 (https=)
ES (1) ES2928684T3 (https=)
HU (1) HUE060732T2 (https=)
MA (1) MA42266A (https=)
MX (2) MX381792B (https=)
MY (1) MY191219A (https=)
PH (1) PH12017502322B1 (https=)
PL (1) PL3315131T3 (https=)
PT (1) PT3315131T (https=)
RU (1) RU2729630C2 (https=)
SG (2) SG11201709260TA (https=)
WO (1) WO2016208744A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
MA42266A (fr) * 2015-06-25 2018-05-02 Taiho Pharmaceutical Co Ltd Agent thérapeutique contre la fibrose
HUE068810T2 (hu) 2017-02-15 2025-01-28 Taiho Pharmaceutical Co Ltd Gyógyászati készítmény
MA50251A (fr) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co Ltd Agent antitumoral et potentialisateur d'effet antitumoral
US20210369739A1 (en) 2018-09-18 2021-12-02 Taiho Pharmaceutical Co., Ltd. Combination therapy of acylthiourea compound and abiraterone
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101998951A (zh) * 2008-04-10 2011-03-30 大鹏药品工业株式会社 酰基硫脲化合物或其盐及其用途
WO2013100014A1 (ja) * 2011-12-28 2013-07-04 大鵬薬品工業株式会社 抗腫瘍剤の効果増強剤
CN107708697B (zh) * 2015-06-25 2021-02-09 大鹏药品工业株式会社 纤维化病治疗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69939586D1 (de) 1998-04-28 2008-10-30 Toshikazu Nakamura Inhibitoren für die gefässneubildung
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
WO2007005668A2 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CN101360748B (zh) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 c-MET抑制剂及其应用
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA025304B1 (ru) * 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101998951A (zh) * 2008-04-10 2011-03-30 大鹏药品工业株式会社 酰基硫脲化合物或其盐及其用途
WO2013100014A1 (ja) * 2011-12-28 2013-07-04 大鵬薬品工業株式会社 抗腫瘍剤の効果増強剤
CN107708697B (zh) * 2015-06-25 2021-02-09 大鹏药品工业株式会社 纤维化病治疗剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKIRA KAWAI ET AL: "Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study", 《INVEST NEW DRUGS》, vol. 39, no. 6, 12 June 2021 (2021-06-12), pages 1559 - 1567 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Also Published As

Publication number Publication date
BR112017028137B1 (pt) 2023-04-04
JP2022009994A (ja) 2022-01-14
SG11201709260TA (en) 2018-01-30
US20200009128A1 (en) 2020-01-09
ES2928684T3 (es) 2022-11-21
MX381792B (es) 2025-03-13
JP2023076632A (ja) 2023-06-01
EP3315131A1 (en) 2018-05-02
SG10201912684TA (en) 2020-03-30
MX2020012989A (es) 2021-02-16
HK1245639A1 (zh) 2018-08-31
JP6974167B2 (ja) 2021-12-01
US20220047572A1 (en) 2022-02-17
EP3315131A4 (en) 2019-02-27
US11690838B2 (en) 2023-07-04
MA42266A (fr) 2018-05-02
PH12017502322B1 (en) 2023-08-30
JP7258985B2 (ja) 2023-04-17
PT3315131T (pt) 2022-10-26
KR20180021682A (ko) 2018-03-05
DK3315131T3 (da) 2022-11-14
MX2017016774A (es) 2018-05-14
RU2017145271A (ru) 2019-07-25
US20200297716A1 (en) 2020-09-24
HUE060732T2 (hu) 2023-04-28
JPWO2016208744A1 (ja) 2018-04-12
CN107708697A (zh) 2018-02-16
US11191759B2 (en) 2021-12-07
MY191219A (en) 2022-06-09
CA2990791A1 (en) 2016-12-29
US10695340B2 (en) 2020-06-30
EP3315131B1 (en) 2022-09-14
AU2016284531A1 (en) 2017-11-30
KR102647942B1 (ko) 2024-03-14
CN107708697B (zh) 2021-02-09
JP7498827B2 (ja) 2024-06-12
EP3973962A1 (en) 2022-03-30
RU2017145271A3 (https=) 2019-12-02
AU2016284531B2 (en) 2020-06-04
PH12017502322A1 (en) 2018-06-25
RU2729630C2 (ru) 2020-08-11
BR112017028137A2 (pt) 2018-08-28
US20180289690A1 (en) 2018-10-11
PL3315131T3 (pl) 2022-12-12
WO2016208744A1 (ja) 2016-12-29
US10449189B2 (en) 2019-10-22

Similar Documents

Publication Publication Date Title
CN107708697B (zh) 纤维化病治疗剂
WO2001003739A1 (fr) Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
KR20230081687A (ko) 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
HK40046439A (en) Therapeutic agent for fibrosis
HK1245639B (zh) 纤维化病治疗剂
US20250099487A1 (en) Composition for preventing or treating pulmonary fibrosis, comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
CA2678920C (en) A medicament for treating chronic obstructive pulmonary disease
JP4243701B2 (ja) ベンズアミド誘導体を有効成分とするリウマチ治療薬
CN121443299A (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
WO2017204163A1 (ja) 肺障害の予防または抑制用医薬
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
JPWO2001003739A1 (ja) スフィンゴシン−１−リン酸受容体アゴニストまたはスフィンゴシン−１−リン酸を有効成分として含有する線維化抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046439

Country of ref document: HK